Beauty Health (SKIN) Expected to Announce Earnings on Thursday

Key Points

• Beauty Health is expected to report its Q2 2025 earnings on August 7, with analysts predicting an earnings per share of ($0.06) and revenue of $74.67 million.
• The company recently reported Q1 earnings of ($0.08) per share, surpassing expectations, and had revenue of $69.60 million, which was above the estimated $63.88 million.
• Goldman Sachs has downgraded its price target for Beauty Health's stock from $1.50 to $1.25, and currently, 93.26% of the company's stock is held by institutional investors.

Beauty Health (NASDAQ:SKIN - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect Beauty Health to post earnings of ($0.06) per share and revenue of $74.67 million for the quarter. Beauty Health has set its FY 2025 guidance at EPS and its Q2 2025 guidance at EPS.

Beauty Health (NASDAQ:SKIN - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.05. The company had revenue of $69.60 million during the quarter, compared to the consensus estimate of $63.88 million. Beauty Health had a negative net margin of 11.94% and a negative return on equity of 67.91%. On average, analysts expect Beauty Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Beauty Health Stock Up 4.2%

Beauty Health stock traded up $0.07 during midday trading on Monday, hitting $1.60. The stock had a trading volume of 196,957 shares, compared to its average volume of 762,209. The stock has a market cap of $200.95 million, a P/E ratio of -3.89 and a beta of 1.20. The business has a fifty day moving average price of $1.77 and a 200 day moving average price of $1.52. The company has a current ratio of 7.47, a quick ratio of 6.43 and a debt-to-equity ratio of 12.01. Beauty Health has a 12 month low of $0.78 and a 12 month high of $2.38.

Institutional Trading of Beauty Health

An institutional investor recently raised its position in Beauty Health stock. Goldman Sachs Group Inc. lifted its position in The Beauty Health Company (NASDAQ:SKIN - Free Report) by 5.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 665,706 shares of the company's stock after acquiring an additional 31,880 shares during the period. Goldman Sachs Group Inc. owned about 0.53% of Beauty Health worth $892,000 as of its most recent SEC filing. Institutional investors and hedge funds own 93.26% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on SKIN. Stifel Nicolaus raised their price target on Beauty Health from $3.00 to $4.00 and gave the stock a "hold" rating in a report on Friday. Canaccord Genuity Group dropped their price objective on shares of Beauty Health from $1.50 to $1.25 and set a "hold" rating on the stock in a report on Monday, May 5th.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.